Abstract
Background: Febrile neutropenia is one of the major acute side effects of intensive treatment in pediatric cancer, necessitating prompt initiation of empirical broad-spectrum antibiotics. Patients may be classified as low or high risk according some risk factors (duration of neutropenia, depth of neutropenia, type of cancer, state of disease, bone marrow involvement, type of treatment, additional health problems). Initial evaluation of the febrile neutropenic child should include the history of the child, a detailed physical examination, blood culture (peripheral and catheter), urinalysis and culture, cultures of lesions.
Result & Conclusion: The standard of care in febrile neutropenic children is that they should be hospitalized, especially if high risk, and should be treated urgently with intravenous wide spectrum empiric antibiotics, the spectrum covering P. Aeruginosa. Empiric treatment should be modified according to culture results and clinical situation. Other options for low risk patients are starting with intravenous treatment and continuing with per oral treatment or giving per oral antibiotic treatment from the beginning.
Keywords: Childhood cancer, febrile neutropenia, pediatrics, diagnosis, treatment, patients.
Current Pediatric Reviews
Title:Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment
Volume: 14 Issue: 3
Author(s): Rejin Kebudi*Hande Kizilocak
Affiliation:
- Cerrahpasa Faculty of Medicine, Pediatric Hematology-Oncology, Istanbul University, Istanbul,Turkey
Keywords: Childhood cancer, febrile neutropenia, pediatrics, diagnosis, treatment, patients.
Abstract: Background: Febrile neutropenia is one of the major acute side effects of intensive treatment in pediatric cancer, necessitating prompt initiation of empirical broad-spectrum antibiotics. Patients may be classified as low or high risk according some risk factors (duration of neutropenia, depth of neutropenia, type of cancer, state of disease, bone marrow involvement, type of treatment, additional health problems). Initial evaluation of the febrile neutropenic child should include the history of the child, a detailed physical examination, blood culture (peripheral and catheter), urinalysis and culture, cultures of lesions.
Result & Conclusion: The standard of care in febrile neutropenic children is that they should be hospitalized, especially if high risk, and should be treated urgently with intravenous wide spectrum empiric antibiotics, the spectrum covering P. Aeruginosa. Empiric treatment should be modified according to culture results and clinical situation. Other options for low risk patients are starting with intravenous treatment and continuing with per oral treatment or giving per oral antibiotic treatment from the beginning.
Export Options
About this article
Cite this article as:
Kebudi Rejin*, Kizilocak Hande, Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment, Current Pediatric Reviews 2018; 14 (3) . https://dx.doi.org/10.2174/1573396314666180508121625
DOI https://dx.doi.org/10.2174/1573396314666180508121625 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Respiratory Stem Cells and Progenitors: Overview, Derivation, Differentiation, Carcinogenesis, Regeneration and Therapeutic Application
Current Stem Cell Research & Therapy Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Current Drug Delivery Age and High-Fat Diet Effects on Glutamine Synthetase Immunoreactivity in Liver and Hippocampus and Recognition Memory in Mice
Current Aging Science The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review
Recent Patents on Inflammation & Allergy Drug Discovery Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Efficacy and Safety of H1-Antihistamines: An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Collagen: The Oldest Scaffold for Tissue Regeneration
Current Tissue Engineering (Discontinued) Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued) Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Encapsulation in Cell Therapy: Methodologies, Materials, and Clinical Applications
Current Pharmaceutical Biotechnology Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Chemistry of Mycophenolic Acid - Synthesis and Modifications Towards Desired Biological Activity
Current Medicinal Chemistry Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Current Molecular Medicine